Reproductive Immunology in IVF: Why the Same Immune Treatment Does Not Suit Every Patient
Reproductive immunology remains one of the most debated areas in IVF, recurrent implantation failure and recurrent pregnancy loss.
Patients who have experienced several failed embryo transfers are often given one of two very different explanations. Some are told that they have an “overactive immune system” and require immune treatment with their next embryo transfer. Others are told that reproductive immunology has little relevance because the evidence supporting many immune tests and treatments remains limited.
Neither position reflects the complexity of implantation or the limitations of the current evidence.
The immune system has an established physiological role in implantation, placental development and early pregnancy. The more difficult question is whether an immune finding in an individual patient is genuinely abnormal, whether it is relevant to that patient’s reproductive history, and whether modifying it is likely to improve the chance of a successful pregnancy.
That distinction becomes particularly important after repeated IVF failure, when patients are understandably searching for an explanation and another treatment option.
Reproductive Immunology Testing: An Abnormal Result Is Not a Diagnosis
One of the common problems in reproductive immunology is interpreting an abnormal immune result in isolation.
Natural killer cells are probably the best example.
A raised peripheral blood NK-cell percentage does not, by itself, demonstrate that NK cells are responsible for implantation failure. Peripheral blood NK cells and uterine NK cells are different populations, while uterine NK cells are normal components of the endometrium and have important physiological roles during implantation and placental development.
Cell numbers are also only one part of immune assessment.
Depending on the clinical situation, interpretation may involve the immune-cell phenotype, activation and function, cytokine patterns, whether testing was performed in peripheral blood or endometrial tissue, and the timing of assessment within the reproductive cycle.
An abnormal laboratory value can otherwise easily become the diagnosis, followed immediately by treatment, without establishing whether that finding is biologically consistent with the patient’s clinical history.
Reproductive immunology testing should answer a clinical question, rather than simply generate more abnormal results.
Successful Implantation Depends on Balance, Not Suppression
Immune dysfunction should not become the default explanation for every failed embryo transfer.
A detailed review of the previous IVF history remains essential.
Embryo competence is fundamental. Maternal age at the time the embryos were created, previous embryology, embryo development and, where applicable, PGT-A results should all be considered.
The uterus and endometrium also require appropriate assessment. This includes the uterine cavity and relevant conditions such as adenomyosis and endometriosis. Previous stimulation cycles, hormonal preparation, embryo transfer protocols and male factors may provide additional information.
Sometimes this review identifies a more convincing explanation for treatment failure.
In other patients, repeated implantation failure or recurrent pregnancy loss remains unexplained despite appropriate assessment. It is within carefully selected patients in this group that more detailed reproductive immunology assessment may become relevant.
Reproductive immunology should therefore form part of a structured investigation of recurrent implantation failure, rather than replace it.
Natural Killer (NK) Cells and IVF Implantation Failure
NK cells have become closely associated with reproductive immunology, but their interpretation is frequently oversimplified.
The term “natural killer cell” itself can create the impression that these cells attack the embryo. This is not an accurate description of their normal role within reproduction.
Uterine NK cells are an important physiological component of the endometrium and early pregnancy. Their functions are considerably more complex than simply being “high” or “low”.
Peripheral blood NK-cell measurements also cannot be assumed to represent what is happening within the endometrium.
Where NK-cell assessment is clinically relevant, the important question may not simply be how many cells are present. Their phenotype, activation state and functional behaviour may provide a different level of information.
This is why an isolated abnormal NK-cell result should not automatically lead to immune treatment.
The result needs to make sense within the wider immune profile and the patient’s reproductive history.
Immune Treatment in IVF: Steroids, Intralipid and IVIG
One of the major difficulties in reproductive immunology is the empirical use of similar immune treatment protocols across very different patients.
These may include corticosteroids, intralipid, intravenous immunoglobulin (IVIG) and other immune-modulating treatments.
The biological assumption behind using the same combination for everyone is difficult to justify.
Immune dysfunction is unlikely to represent one single condition.
One patient may demonstrate a predominantly inflammatory cytokine pattern. Another may show altered NK-cell activation or function. A different patient may demonstrate a pattern involving immune regulation rather than excessive activation. Some patients undergoing extensive testing will have abnormal results whose clinical significance remains uncertain.
These patients should not automatically be considered biologically equivalent simply because they have all experienced recurrent implantation failure or recurrent miscarriage.
Nor should they automatically receive the same treatment.
Importantly, more immune suppression does not necessarily mean better implantation.
Normal implantation and placental development require appropriate immune activity. The objective of reproductive immunology cannot therefore simply be to suppress the maternal immune system.
Treatment should follow interpretation, rather than interpretation being constructed to justify treatment.
Reproductive Immunology and Immune Phenotyping
A more useful direction is to move away from describing patients broadly as having “immune infertility” and instead identify the dominant immune pattern, or immune phenotype, where one can reasonably be demonstrated.
A predominantly inflammatory pattern is not necessarily equivalent to altered cellular activation. Abnormal NK-cell function is different from an isolated change in NK-cell numbers. Evidence suggesting altered immune regulation may represent another biological process again.
The purpose of immune phenotyping is not to create more diagnoses or order increasingly extensive panels of tests.
It is to avoid placing biologically different patients into the same category and treating them identically.
There is also another important dimension: when the abnormality occurs.
Reproductive Immunology and the Timing of Implantation
The immune environment is dynamic throughout reproduction.
The immunological environment before implantation is not identical to that during the implantation window, and both differ from the adaptations occurring during early pregnancy and placental development.
An immune finding detected at one stage therefore cannot automatically be assumed to have the same relevance at another.
This raises a more useful set of clinical questions than simply asking whether a patient has an “immune problem”:
What immune pattern is present?
At which reproductive phase is it present?
Is it consistent with the patient’s history of implantation failure or pregnancy loss?
And is there sufficient evidence to justify intervention?
Timing may also help explain some of the conflicting results within reproductive immunology research.
If biologically different patients are grouped together under broad diagnoses such as recurrent implantation failure or recurrent pregnancy loss and are then given the same intervention at the same stage, a potential benefit within a particular subgroup may be difficult to detect across the entire study population.
Better patient classification is therefore relevant not only to clinical practice, but also to future research.
ERIF: A Phenotype- and Phase-Directed Approach to Reproductive Immunology
These limitations formed part of the rationale behind the Elgheriany Reproductive Immunology Framework (ERIF).
ERIF proposes a phenotype- and phase-directed approach to the interpretation of reproductive immune dysfunction.
Rather than treating reproductive immunology as a single condition, the framework considers both the dominant immune phenotype and the reproductive phase during which that abnormality may be clinically relevant.
The concept is straightforward:
different immune patterns should not automatically receive the same treatment, and the same immune finding may not have identical significance at every stage of reproduction.
ERIF does not mean that a proven treatment currently exists for every proposed immune phenotype. The framework is intended to provide a structured approach to interpretation and future research. It is not a validated treatment algorithm, and this distinction is important.
The objective is to move reproductive immunology away from increasingly complicated empirical protocols and towards better patient selection and more biologically coherent treatment strategies.
Reproductive Immunology Treatment Should Follow Clinical Interpretation
After repeated IVF failure, the pressure to try something different is understandable.
Another unsuccessful embryo transfer may represent years of fertility treatment, considerable financial cost and significant emotional burden. Adding another medication can therefore feel preferable to repeating the same treatment.
But adding treatment is not necessarily the same as improving treatment.
Any immune-modulating intervention should have a reasonable clinical and biological rationale based on the patient’s history, the pattern and consistency of the immune findings, and the available evidence supporting that particular intervention.
In some patients, treatment may be reasonable.
In others, further investigation may be more appropriate.
And sometimes an abnormal immune result should not be treated at all, because there is insufficient evidence that correcting the laboratory abnormality will improve the chance of a live birth.
That decision is equally important.
The Future of Reproductive Immunology in IVF
Significant gaps remain in the evidence surrounding reproductive immunology, recurrent implantation failure and recurrent pregnancy loss.
The next step should not be another universal immune protocol.
It should be better definition of the patients being investigated and treated.
Which patients demonstrate reproducible immune dysregulation?
What is the dominant immune phenotype?
At which reproductive phase does it become relevant?
Does the finding correlate with the patient’s implantation or pregnancy history?
And most importantly, does targeting that specific abnormality improve live birth, rather than simply changing an immune marker on a laboratory report?
These are more difficult questions than asking whether NK cells are elevated or whether steroids should be added to the next embryo transfer.
But they are the questions that matter.
Reproductive immunology needs to sit between two extremes. Immune treatments should not be added indiscriminately after failed IVF, but the biological role of the immune system in implantation and early pregnancy should not be dismissed simply because the clinical evidence remains incomplete.
The aim is not to give more patients immunotherapy.
The aim is to identify the right patient, understand the relevant immune phenotype and reproductive phase, and intervene only when there is a defensible biological and clinical rationale.
Dr Ahmed Elgheriany
MBBS MSc MRCOG
Consultant Gynaecologist & Fertility Specialist
Special Interest in Reproductive Immunology
Author of the Elgheriany Reproductive Immunology Framework (ERIF)
This article is intended for general educational purposes and does not replace individual medical assessment or personalised treatment advice.
Comments